Cargando…

Afatinib-Associated Cutaneous Toxicity: A Correlation of Severe Skin Reaction with Dramatic Tumor Response in a Woman with Exon 19 Deletion Positive Non-Small-Cell Lung Cancer

Epidermal growth factor receptor (EGFR) inhibitors are biological factors used in the treatment of non-small-cell lung cancers (NSCLC) that are positive for EGFR mutations. Afatinib is one such drug that has been approved for use in this capacity. Cutaneous toxicity is the second most commonly repor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Osborn, Lindsay P, Cohen, Philip R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2016
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045329/ https://www.ncbi.nlm.nih.gov/pubmed/27725919 http://dx.doi.org/10.7759/cureus.763

Ejemplares similares

Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare EGFR Exon 20 Mutation
por: Zöchbauer-Müller, Sabine, et al.
Publicado: (2021)

Toxic epidermal necrosis associated with afatinib: A case report and literature review
por: Yang, Wei, et al.
Publicado: (2023)

Concurrent Afatinib and Whole-Brain Radiotherapy in Exon 19-del-EGFR Mutant Lung Adenocarcinoma: A Case Report and Mini Review of the Literature
por: Eze, Chukwuka, et al.
Publicado: (2017)

Co-Occurring Alterations of ERBB2 Exon 20 Insertion in Non-Small Cell Lung Cancer (NSCLC) and the Potential Indicator of Response to Afatinib
por: Yuan, Bo, et al.
Publicado: (2020)

Successful Treatment of Lung Adenocarcinoma with Epidermal Growth Factor Receptor Compound Mutations Involving Exon 19 Deletion and Exon 20 Insertion by Afatinib
por: Ikeuchi, Tomoyuki, et al.
Publicado: (2019)

Linear Malignant Melanoma In Situ: Reports and Review of Cutaneous Malignancies Presenting as Linear Skin Cancer
por: Cohen, Philip R
Publicado: (2017)

Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy
por: Tokudome, Nahomi, et al.
Publicado: (2020)

Dramatic response to neoadjuvant savolitinib in marginally resectable lung adenocarcinoma with MET exon 14 skipping mutation: A case report and literature review
por: Tian, Jiangfang, et al.
Publicado: (2022)

Effective Treatment With Afatinib of Lung Adenocarcinoma With Leptomeningeal Metastasis Harboring the Exon 18 p.G719A Mutation in the EGFR Gene Was Detected in Cerebrospinal Fluid: A Case Report
por: Ma, Chunhua, et al.
Publicado: (2020)

Dramatic Response of an Aggressive Chest Wall Recurrence to Hyperthermia, Radiation, and Chemotherapy
por: Cohen, Justin, et al.
Publicado: (2017)

Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations
por: Chen, Yi-Chieh, et al.
Publicado: (2021)

The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations
por: Yang, Chih-Jen, et al.
Publicado: (2017)

Case report: Dramatic response to pralsetinib in an elderly patient with advanced RET-fusion positive papillary thyroid carcinoma
por: Nannini, Margherita, et al.
Publicado: (2022)

Successful Treatment of Afatinib Reversing Epidermal Growth Factor Receptor Exon19Deletion/G724S Mutation Resistance Guided by Protein‐Drug Docking
por: Yu, Nian, et al.
Publicado: (2021)

Skin Directed Therapy in Cutaneous T-Cell Lymphoma
por: Tarabadkar, Erica S., et al.
Publicado: (2019)

Detection of internal exon deletion with exon Del
por: Guo, Yan, et al.
Publicado: (2014)

Afatinib-induced Interstitial Lung Disease Successfully Treated with Corticosteroids: Case Report and Review of the Literature
por: Jobe, Amanda L, et al.
Publicado: (2018)

First reported case of afatinib‐associated toxic megacolon
por: Kwok, Wang Chun, et al.
Publicado: (2018)

Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
por: Lin, Ling, et al.
Publicado: (2020)

Appropriate Sequence for Afatinib and Cisplatin Combination Improves Anticancer Activity in Head and Neck Squamous Cell Carcinoma
por: Longton, Eleonore, et al.
Publicado: (2018)

A Novel Oncogenic Driver in a Lung Adenocarcinoma Patient Harboring an EGFR-KDD and Response to Afatinib
por: Chen, Dong, et al.
Publicado: (2020)

Non-small cell lung cancer harboring EGFR G724S mutation and exon 19 deletion responded to afatinib monotherapy after multiple lines of target therapies
por: Cortiula, Francesco, et al.
Publicado: (2022)

Clinical-radiomics-based treatment decision support for KIT Exon 11 deletion in gastrointestinal stromal tumors: a multi-institutional retrospective study
por: Zhang, Yu, et al.
Publicado: (2023)

Dramatic Regression of a Fungating Breast Lesion Treated with Radiation Therapy
por: Gao, Robert W, et al.
Publicado: (2017)

Prophylactic Dermatologic Treatment of Afatinib-Induced Skin Toxicities in Patients with Metastatic Lung Cancer: A Pilot Study
por: Fuggetta, Maria Pia, et al.
Publicado: (2019)

Identification and Validation of Afatinib Potential Drug Resistance Gene BIRC5 in Non-Small Cell Lung Cancer
por: Zhu, Xiaoxi, et al.
Publicado: (2021)

Cutaneous Metastasis From Tonsillar Squamous Cell Carcinoma: Report and Review of the Literature
por: Bari, Omar, et al.
Publicado: (2017)

Metastatic Breast Cancer Coexisting With HER-2 Amplification and EGFR Exon 19 Deletion Benefits From EGFR-TKI Therapy: A Case Report
por: Jing, Wei, et al.
Publicado: (2020)

Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies
por: Passaro, Antonio, et al.
Publicado: (2021)

Aggressive angiomyxoma of the pelvis and abdominal wall: Dramatic response to chemical ablation therapy
por: Li, Liu, et al.
Publicado: (2023)

DPYD Exon 4 Deletion Associated with Fluoropyrimidine Toxicity and Importance of Copy Number Variation
por: Wigle, Theodore J., et al.
Publicado: (2023)

A dramatic presentation of an unusual form of cutaneous lymphoma
por: Yang, Sam Shiyao, et al.
Publicado: (2015)

Bioinformatic-based genetic characterizations of neural regulation in skin cutaneous melanoma
por: Wang, Fengdi, et al.
Publicado: (2023)

Case Report: Dramatic Response to Crizotinib in a Patient With Non-Small Cell Lung Cancer Positive for a Novel ARL1-MET Fusion
por: Ma, Qing, et al.
Publicado: (2022)

Lung Adenocarcinoma Patient Harboring EGFR-KDD Achieve Durable Response to Afatinib: A Case Report and Literature Review
por: Zhao, Lingling, et al.
Publicado: (2021)

Inconsistent clinical outcomes following afatinib treatment in NSCLC patients harboring uncommon epidermal growth factor receptor mutation
por: Dong, Wei, et al.
Publicado: (2022)

CNS efficacy of afatinib as first-line treatment in advanced non-small cell lung cancer patients with EGFR mutations
por: Kang, Liping, et al.
Publicado: (2023)

Budget Impact Analysis of Afatinib for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 Substitution Mutations in a U.S. Health Plan
por: Graham, Jonathan, et al.
Publicado: (2018)

Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction
por: Viscuse, Paul V., et al.
Publicado: (2021)

First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression
por: Schuler, Martin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_g4quktrhhgj7dh81l8p579og8e